The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis

[1]  G. Follows,et al.  Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients , 2021, British journal of haematology.

[2]  S. Hohaus,et al.  Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study , 2020, Leukemia.

[3]  U. Jaeger,et al.  Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy , 2019, Leukemia.

[4]  Michael L. Wang,et al.  Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis , 2018, Haematologica.

[5]  K. Maddocks.  Update on mantle cell lymphoma. , 2018, Blood.

[6]  S. Novaković,et al.  Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome , 2017, British journal of clinical pharmacology.

[7]  E. Kimby,et al.  15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau , 2016, British journal of haematology.

[8]  W. Klapper,et al.  Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials , 2016, Leukemia.

[9]  B. Hill,et al.  Is rituximab sub‐optimally dosed in indolent B cell lymphoma? , 2016, British journal of haematology.

[10]  G. Follows,et al.  The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial , 2016, Haematologica.

[11]  Alexandra G. Smith,et al.  Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network , 2015, British Journal of Cancer.

[12]  N. Schmitz,et al.  Suboptimal dosing of rituximab in male and female patients with DLBCL. , 2014, Blood.

[13]  G. Salles,et al.  CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.

[14]  R. Greil,et al.  Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response , 2012, Haematologica.

[15]  Carsten Müller,et al.  The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. , 2012, Blood.

[16]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[17]  W. Klapper,et al.  Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma , 2008, Haematologica.

[18]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[19]  E. Hoster,et al.  Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas , 2006, Cancer.

[20]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[21]  M. Ladetto,et al.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.